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CHAPTER IV 
 
 
RESULTS AND DISCUSSION 
 
 
4.1 PRODUCTION OF STERILE LARVAL EXTRACT FOR 
ANTIBACTERIAL  ASSAYS 
 
In the present study, homogenization of L. cuprina late second-instar larvae was 
performed manually using 15-ml glass Dounce homogenizer. This classical manual 
method of homogenization uses mechanical force applied by hand to disrupt tissue and 
cells gently and effectively. In a dounce system, the mortar (cylinder made of 
borosilicate glass) and pestle come bundled and are specially crafted for use with each 
other to ensure a tighter fit and improves homogenization efficiency. During 
homogenization, an adequate amount of methanol was added from time to time and the 
lamina flow of methanol through the annular space between the pestle and the mortar 
wall resulted in different fluid (methanol) speeds existing over the diameter of the cell 
and the resulting shear forces disrupted the cell and extracted the cellular content 
(Figure 4.1a) (Dennison 2003). Prior to homogenization, the Dounce homogenizer was 
autoclaved to avoid contamination.  
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Figure 4.1a: Enlarged view of a Dounce homogenizer 
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 Figure 4.1b illustrates the final product of methanol extraction of L. cuprina late 
second-instar larvae after methanol-homogenization, centrifugation and subsequent 
vacuum-concentration of the resulted larval supernatant. The final product, L. curpina 
larval extract and its suspension (Figure 4.1c) appears in bright yellow colour. 
However, Bexfield et al. (2004) reported that the collected L. sericata larval 
excretions/secretions (ES) was dark-brown in colour. This suggested that the active 
ingredient(s) retained in L. cuprina larval extract is/are different to that/those of L. 
sericata larval ES. In other words, L. cuprina larval extract might possess different 
antibacterial constituents against bacteria as compared to L. sericata larval ES.  
 
 Collection of excretions/secretions (ES) from live, aseptically reared, late 
second-instar larvae is time-consuming and therefore costly to perform as series of 
aseptic measures would need to be taken to maintain the sterility of larvae and larval 
ES. Besides, it is difficult to assure and keep the larvae constantly and actively 
excreting in order to attain a high yield of ES. Thomas et al. (1999) have reported that 
the volume of secretions from sterile larvae of L. sericata
was limited. Hence, the present study adopted methanol extraction method to produce 
whole-body extract from late second-instar larvae of L. cuprina for antibacterial assays 
instead.    
 
 Another rationale of producing whole-body extract instead of ES is that the 
whole-body extract may contain the entire bio-products of larvae, which included feces, 
cutaneous   and   oral   secretions. There was evidence to substantiate that the active 
antibacterial agent(s) was/were contained in the feces as Robinson and Norwood (1933) 
reported that the content of the hind intestine of L. sericata larvae which had fed within  
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Figure 4.1b: Vacuum-concentrated larval extract of L. cuprina 
 
 
 
 
Figure 4.1c: Suspension of L. cuprina larval extract (200 mg/ml) for antibacterial 
assays 
   
  
42 
 
osteomyelitis wounds was sterile, while those of the crop and stomach were heavily 
contaminated.  
 
 In the present study, non sterile, late second-instar L. cuprina larvae that had 
been reared on raw, decaying cow liver were employed in the production of larval 
extract, in order to simulate as closely as possible conditions encountered in maggot 
therapy (Simmons 1935). Nevertheless, the larval extract was cultured for sterility prior 
to use. Only larval extract that had been proven sterile and free from bacterial 
contaminants was used for antibacterial assays. Findings from other studies (Simmons 
1935; Huberman et al. 2007) have demonstrated that the larval ES or extract of L. 
sericata would be collected under septic conditions and then sterilized without apparent 
loss of potency against tested bacteria. Moreover, excretion from sterile larvae was also 
considered less typical of that produced by larvae worked in bacteria-infected wounds 
(Simmons, 1935). 
 
4.2 ANTIBACTERIAL ASSAYS 
 
4.2.1 Turbidometric Assay 
Turbidometric assay (TB) or spectrophotometric assay was adopted to demonstrate the 
inhibition effects of L. cuprina larval extract on the growth of the seven selected wound 
pathogenic bacteria. Bacterial growth can be defined as the orderly increase in the 
quantity of all cellular components and in the number of cells. Due to the limited 
increase in cell size and rapid cell division, bacterial growth is often measured by 
increase in cell number.  
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 In turbidometry, an increment in turbidity or optical density (OD) generally 
indicates an increase in the number of bacteria present, although under certain 
circumstances a small increase in OD may be due to an increase in bacterial size caused 
by swelling prior to lysis (Thomas et al. 1999). Nonetheless, this assay can be 
automated and provides a rapid, convenient method for monitoring changes in cell 
number in small volume of bacterial suspension. This simple and rapid assay allows 
extensive kinetic studies even in the presence of low larval extract concentrations and 
volumes and is capable of detecting inhibitory level below those recorded for well or 
disc diffusion assay (Patton et al. 2006). 
 
 In this study, both bacterial growth in the controls (without larval extract) and 
test samples (with larval extract) were expressed in the ratio of OD before incubation to 
OD after incubation. A bigger OD ratio implies higher growth rate. Results from the TB 
assay (Figure 4.2.1a) showed that there was a conspicuous difference between the OD 
ratio of test samples and controls.  
 
 Further statistical analysis by independent Student’s t-test (Table 4.2.1a) had 
demonstrated that the in vitro growth of S. aureus, MRSA, S. epidermidis, S. pyogenes, 
K. pneumoniae, P. aeruginosa and E. coli in the test samples (overnight incubation with 
larval extract) were significantly lower as compared to the normal bacterial growth in 
the controls. These results indicated that L. cuprina larval extract possessed significant 
(p<0.001, n=30) antibacterial activity against all bacteria tested, which are the potential 
Gram-positive and Gram-negative wound pathogen.  
 
 The results obtained are partially in agreement with the previously published 
studies, in   which  the  investigators  concluded  that   L. sericata  larval  ES  exhibited  
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Figure 4.2.1a: Effect of Lucilia cuprina larval extract on bacterial growth 
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Table 4.2.1a: Comparison of mean OD ratio of controls and test samples at 630 nm for 
seven bacteria tested  
 
Bacterial Species TB Assay Mean ± SD t-statistics 
a 
(df) p value 
S. aureus Control  17.02 ± 1.88 25.26 (18) *<0.001 
 Test Sample 1.82  ±  0.26   
MRSA Control  23.23 ± 4.32 15.58 (18) *<0.001 
 Test Sample 1.80  ± 0.47   
S. epidermidis Control  18.67 ± 0.99 50.95 (18) *<0.001 
 Test Sample 1.48  ±  0.40   
S. pyogenes Control  12.23 ± 2.09 16.46 (18) *<0.001 
 Test Sample 1.28  ±  0.21   
K. pneumoniae Control  19.82 ± 1.51 39.19 (18) *<0.001 
 Test Sample 1.11  ±  0.09   
P. aeruginosa Control  34.84 ± 3.29 31.87 (18) *<0.001 
 Test Sample 1.54 ±  0.30   
E. coli Control  27.89 ± 1.22 66.57 (18) *<0.001 
 Test Sample 1.25  ±  0.33   
 
a
 Two-tailed unpaired Student’s t-test 
*Significant value at p=0.05 
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significant inhibitory effects against a range of Gram-positive and Gram-negative 
bacteria,  which  were  S. aureus, a clinical isolate of  MRSA,  E. coli and P. aeruginosa 
(Bexfield et al. 2004). However, the growth of S. epidermidis was not inhibited by the 
larval ES from L. sericata even with an increased dose of larval ES or a reduced 
bacterial inoculum (Bexfield et al. 2008) using the TB assay. This suggested that L. 
cuprina larval extract has a broader spectrum of antibacterial activity compared to L. 
sericata larval ES. 
 
 However, a study published recently by Arora et al. (2010) reported opposing 
results though they employed the same blowfly species L. cuprina larvae for 
antibacterial bioassays. In their study, one of the methods that they used to extract the 
metabolites from late second-instar larvae was by incubating 500 larvae in a 200 ml-
conical flask with 2 ml phosphate-buffered saline (PBS) for 24 hours. The resultant 
liquid in the flask was pipetted out, centrifuged at 10, 000 x g for five minutes and 
sterilized using 0.2 µm syringe filter. Nonetheless, they failed to demonstrate the 
antibacterial activity of L. cuprina larval ES against methicillin-susceptible S. aureus 
(MSSA) and E. coli but have instead observed bacterial growth promotion after ES 
addition compared to the controls. 
 
 Nevertheless, with some modifications in the above method, Arora et al. (2010) 
incubated 100 larvae in 200 µl of PBS in dark for one hour, then collected and 
processed the final larval ES as mentioned above. In contrast to the results obtained 
previously, they were able to detect 30% of bacterial growth inhibition from the initial 
bacterial inoculum for MSSA. However, the ES had no significant inhibition against E. 
coli. 
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 The contrasting results between the present study and Arora et al. (2010) though 
employing the same blowfly species could be due to heavier bacterial inocula (2.0 x 10
7
 
cells/ml for S. aureus  and 1.5 x 10
6
 for E. coli) and different method of extraction for 
larval metabolites employed by Arora et al. In addition, they also explained that the 
antibacterial factor(s) in the collected ES may be present in much diluted form to exert 
significant antibacterial activity since they did not concentrate the collected ES via 
lyophilization or other dehydration methods. 
 
 Additionally, statistical analyses by independent Student’s t-test revealed that 
the mean OD ratios for controls and test samples were significantly different between 
the selected Gram-positive and Gram-negative bacteria. In the present study, the mean 
OD ratios for the Gram-positive bacteria in the controls were 35.36% lower than those 
of the Gram-negative bacteria (Table 4.2.1b). These indicated that the Gram-negative 
bacteria grew better than the Gram-positive bacteria in the same growth medium (BHI 
broth). Nonetheless, the inhibitory effect of the larval extract was significantly more 
pronounced on the Gram-negative bacteria as the OD or growth ratios of the Gram-
negative bacteria in the test samples were 23.08% lower than those of the Gram-positive 
bacteria (Table 4.2.1c).   
 
 On the other hand, Figure 4.2.1b demonstrated the potency of larval extract in 
inhibiting bacterial growth. The potency or effectiveness of larval extract was indicated 
by the percentage of decrement in the OD ratio of test samples in comparisons with the 
OD ratio of the corresponding controls. The results showed that the larval extract 
exhibited high potency against all tested bacteria, with an average inhibitory potency of 
92.51 + 2.75% (Table 4.2.1d). However, statistical analysis by one-way ANOVA 
(Table 4.2.1d) substantiated that the larval extract was significantly potent towards at  
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Table 4.2.1b: Mean OD ratios for controls between the Gram-positive and Gram-
negative bacteria  
 
Bacterial Species Mean ± SD t-statistics 
a 
(df) p value 
Gram-positive 
- S. aureus 
- MRSA 
- S. epidermidis 
- S. pyogenes 
 
17.79 ± 4.72 -7.20 (68) *<0.001 
Gram-negative 
K. pneumoniae 
P. aeruginosa 
E. coli 
27.52 ± 6.59   
 
a
 Two-tailed unpaired Student’s t-test 
*Significant value at p=0.05 
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Table 4.2.1c: Mean OD ratios for test samples between the Gram-positive and Gram-
negative bacteria  
 
Bacterial Species Mean ± SD t-statistics 
a 
(df) p value 
Gram-positive 
- S. aureus 
- MRSA 
- S. epidermidis 
- S. pyogenes 
 
1.60 ± 0.41 3.31 (68) *<0.001 
Gram-negative 
K. pneumoniae 
P. aeruginosa 
E. coli 
1.30 ± 0.31   
 
a
 Two-tailed unpaired Student’s t-test 
*Significant value at p=0.05 
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Figure 4.2.1b: Potency of Lucilia cuprina larval extract against the seven bacteria tested 
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Table 4.2.1d: Mean potency of L. cuprina larval extract against bacteria  
 
Bacterial Species Potency of Larval Extract 
(%) 
(Mean ± SD) 
F-statistics 
a 
(df) p value 
S. aureus 89.13 ± 2.29 16.80 (6, 63) *<0.001 
    
MRSA 91.92 ± 2.87   
    
S. epidermidis 91.99 ± 2.49   
    
S. pyogenes 89.13 ± 2.99   
    
K. pneumoniae 94.36 ± 0.87   
    
P. aeruginosa 95.55 ± 0.87   
    
E. coli 95.53 ± 1.15   
    
 
Average Potency 
 
92.51 + 2.75 
 
  
 
a
 One-way ANOVA test 
*Significant value at p=0.05 
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least one of the bacteria tested (ANOVA, p<0.001). Subsequent post-hoc multiple 
comparison test revealed that the Gram-negative bacteria P. aeruginosa, E. coli and K. 
pneumoniae were significantly sensitive to the antibacterial effects of larval extract as 
compared to the Gram-positive bacteria (Tukey’s HSD Post-hoc Test, p<0.05). The in 
vitro growth of P. aeruginosa, E. coli and K. pneumonia significantly decreased by 
95.55+ 0.87%, 95.53 + 1.15% and 94.36 + 0.87%, respectively in comparisons to the 
corresponding controls. 
 
 Nevertheless, in the study conducted by Thomas et al. (1999), ES produced by 
sterile L. sericata larvae through repeated washing with sterile water or buffer exhibited 
significant inhibitory  effect  on  the  growth  of  S. aureus,  but partial  growth  
inhibition  of  MRSA and P. aeruginosa, and even enhanced the growth of E. coli. The 
possible explanations for the discrepancies between their results and the present study 
could be the different experimental conditions, including the use of different species of 
larvae (L. sericata) and larval product (L. sericata larval ES), and a shorter incubation 
period (five-hour). 
 
 On the other hand, in contrast to the results obtained by Thomas et al. (1999), 
the significant inhibitory effect on P. aeruginosa in the present study was supported by 
Huberman et al. (2007). They isolated and identified three molecules with antibacterial 
activity from the haemolymph extracts of non-sterile L. sericata larvae. The three 
isolated molecules, p-hydroxybenzoic acid, p-hydroxyphenylacetic acid and proline 
diketopiperazine revealed antibacterial activity against P. aeruginosa, and the inhibitory 
effect was even more significant when these molecules were tested in combination. 
These findings suggested that the significant bacterial growth inhibition of L. cuprina 
larval extract against pathogen might not be only contributed by one antibacterial agent 
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alone, but could be pronounced by the synergistic effect of the corresponding 
antibacterial agents in the larval extract. 
 
4.2.2 Colony-Forming Unit Assay 
Colony-forming unit (CFU) assay is used to enumerate the number of viable bacteria 
cells in a sample containing bacteria. In conjunction with the TB assay, it is always used 
to elucidate the antibacterial properties (bactericidal or bacteriostatic) of an 
antimicrobial agent. The underlying theory for CFU assay is that a single bacterium will 
divide or multiply via binary fission to produce a single, macroscopic colony visible to 
the naked eye on agar plate. Therefore by counting the number of colonies that 
developed, colony-forming units (CFUs), and by taking into account the dilution 
factors, the concentration of bacteria in the original sample can be determined. Plates 
producing 30 to 300 colonies are considered within the countable range. Plates with 
CFUs fewer than 30 are not acceptable statistically, whilst more than 300 colonies on a 
plate are likely to produce colonies too close to each other to be distinguished as 
individual CFU (Black 2004). 
 
 In CFU assay, the potency of L. cuprina larval extract was determined by 
comparing the CFU/ml produced on the test sample plates (bacterial inocula incubated 
overnight with 100 mg/ml larval extract) with the control plates (overnight incubation 
without larval extract). Statistical analyses by independent Student’s t-test (Table 
4.2.2a) affirmed that L. cuprina larval extract significantly killed and hence impeded the 
formation of S. epidermidis, K. pneumoniae, P. aeruginosa and E.coli (p<0.001, n=10) 
colonies on the BHIA plates as compared to the colonies formed on the BHIA control 
plates. 
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Table 4.2.2a: Comparison of mean CFU/ml of control and test sample plates for seven 
bacteria tested  
 
Bacterial Species CFU Assay Mean ± SD 
( x10
9
 CFU/ml) 
t-statistics 
a 
(df) p value 
S. aureus Control  1.07 ± 0.05 0.72 (18) 0.481 
 Test Sample 1.05 ± 0.07   
MRSA Control  1.10 ± 0.05 -0.84 (18) 0.412 
 Test Sample 1.12 ± 0.02   
S. epidermidis Control  0.58 ± 0.05 8.21 (18) *<0.001 
 Test Sample 0.35 ± 0.07   
S. pyogenes Control  2.14 ± 0.03 1.76 (18) 0.096 
 Test Sample 1.98 ± 0.29   
K. pneumoniae Control  0.63 ± 0.04 4.55 (18) *<0.001 
 Test Sample 0.53 ± 0.05   
P. aeruginosa Control  0.9 ± 0.06 37.44 (18) *<0.001 
 Test Sample 0.07 ± 0.02   
E. coli Control  1.49 ± 0.13 13.93 (18) *<0.001 
 Test Sample 0.64 ± 0.14   
 
a
 Two-tailed unpaired Student’s t-test 
*Significant value at p=0.05 
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Figure 4.2.2a: Effect of Lucilia cuprina larval extract on bacterial viability using CFU 
assay 
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 On the other hand, Figure 4.2.2a illustrated the viability of tested bacteria in the 
presence of larval extract. The decrement of CFU/ml in the test sample plates was 
expressed as a percentage of control CFU/ml. The higher the decrement in the CFU/ml 
of the test sample plates as compared to the controls, the greater is the number of cells 
being killed, and hence the stronger is the bactericidal or killing effect of larval extract. 
The results revealed that there were only 4.25 ± 3.44%, 4.31 + 3.12% and 3.65 ± 3.09% 
decrement of CFU/ml in the test sample plates of S. aureus, MRSA and S. pyogenes 
respectively as compared to the corresponding control plates. These implied that as high 
as 95.75 ± 3.44% of S. aureus, 95.69 ± 3.12% of MRSA and 96.35 ± 3.09% of S. 
pyogenes cells were still viable after overnight incubation in 100 mg/ml L. cuprina 
l a r v a l  e x t r a c t  a s  c o m p a r e d  t o  t h e  c o n t r o l  p l a t e s  ( T a b l e  4 . 2 . 2 b ) . 
 
 The recovery of these bacteria in the solid BHI media (CFU assay) after 
inhibited by the larval extract in broth media (TB assay) indicated that the larval extract 
did not kill the bacteria but instead, restrained bacterial reproduction and this suggested 
a bacteriostatic or growth-inhibiting effect on the corresponding bacteria. When the 
aliquots were transferred  from  the  broth  medium  (with larval extract)  to the  agar  
plates,  the  growth-stunted but viable bacterial cells  resumed  their  growth  and  
formed  macroscopic  colonies  on the plates as the quantity of larval extract carried 
over would not be in adequate concentrations and volumes to exert the bacteriostatic 
effect.  
 
On the other hand, CFU assay (Figure 4.2.2a) also revealed that 39.76 + 8.55% 
of S. epidermidis, 15.40 ± 3.98% of K. pneumoniae, 91.72 + 1.82% of P. aeruginosa 
(Figure 4.2.2b) and 57.55 + 7.16 of E. coli (Figure 4.2.2c) cells were killed as a result of 
the bactericidal or killing effect of L. cuprina larval extract. Amongst these statistically  
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Table 4.2.2b: Percentage of viable bacterial cells in the test sample plates after 
overnight incubation with L. cuprina larval extract 
 
Bacterial Species N Percentage of Viable Cells 
(Mean ± SD) 
S. aureus 10 95.75 ± 3.44 
   
MRSA 10 95.69 ± 3.12 
   
S. epidermidis 10 60.24 ± 8.55 
   
S. pyogenes 10 96.35 ± 3.09 
   
K. pneumoniae 10 84.60 ± 3.98 
   
P. aeruginosa 10 8.28 ± 1.82 
   
E. coli 10 42.45 ± 7.16 
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Figure 4.2.2b: Potent bactericidal effect of L. cuprina larval extract on P. aeruginosa 
cultures (upper plates are the controls whilst lower are test samples) 
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Figure 4.2.2c: Potent bactericidal effect of L. cuprina larval extract on E. coli cultures 
(upper plates are the controls whilst lower are test samples) 
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significant bactericidal effects, it was noticeable that the Gram-negative P. aeruginosa 
was most sensitive to the larval extract as the cell viability of P. aeruginosa in the test 
sample plates was only less than 10% (8.28 + 1.82%) on BHI agar (Figure 4.2.2b).  
 
 This result once again agreed with the findings from Huberman et al. (2007) that 
the   haemolymph   extract   of   non-sterile   L. sericata   larvae   exhibited   significant 
bactericidal effect on P. aeruginosa. One of the identified bactericides from the extract 
was p-hydroxybenzoic acid, a phenol derivative with known antibacterial activity and is 
used as preservatives in food and cosmetic industries (Friedman et al. 2003). Besides, a 
recent research undertaken by Barnes et al. (2010) demonstrated that L. sericata larval 
ES produced by 1000 mg of larvae per ml of distilled water was more potent on the 
Gram-negative bacteria E. coli and P. aeruginosa.  
 
 However, there are contradictory reports that the results obtained did not agree 
with those reported by investigators worked on L. sericata larval ES. In the study 
conducted by van der Plas et al. (2007), sterile larval ES did not affect P. aeruginosa 
viability. Besides, in 1998, Jaklic et al. had also failed to demonstrate the growth 
inhibitory and bactericidal effects of filter-sterilized L. sericata larval extract on P. 
aeruginosa and E.coli. These results seemed to support the earlier hypothesized 
statement that L. cuprina larval extract exhibits different inhibition capacity from L. 
sericata larval ES. 
 
 As a whole, it is not unusual for antibacterial agents to exert both bacteriostatic 
and bactericidal activity depending on the bacteria tested and the concentrations of the 
antibacterial agent achieved at various infection sites, whilst clinically the importance of 
bacteriostatic versus bactericidal effect on microorganisms is under dispute. 
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Bacteriostatic drugs inhibit the growth and replication of microorganisms and the final 
eradication of pathogens at the infection sites is always accomplished by the immune 
system of the host. The bactericidal drugs though kill and thus eradicate pathogen, yet 
in heavily colonized infection site, the host’s immune system is equally crucial for the 
final eradication of the pathogens. Moreover, the supposed superiority of bactericidal 
effect over bacteriostatic is of little clinical relevance when treating particularly patients 
with uncomplicated infections and non-compromised immune systems (Pankey and 
Sabath 2004).  
 
 In view of these, though L. cuprina larval extract exerted bacteriostatic effect on 
the growth of most of the tested bacteria, however, the larval capability in eliminating 
pathogens from the infected chronic wounds shall not be underestimated as it should be 
realized that the medicinal larvae that work in the wounds are continuously present to 
exert the antibacterial effect and accomplish more than disinfection of the wounds 
(Simmons 1935). 
 
4.2.3 Agar Well Diffusion Assay 
Another antibacterial assay, the agar well diffusion or zone inhibition assay was 
performed to determine the susceptibility or resistance of the seven selected wound 
pathogenic bacteria to L. cuprina larval extract. Diffusion or movement of antibacterial 
molecules through the agar matrix, and the tendency of the antimicrobial molecules to 
move from a region of high concentration (larval extract-containing well) to the 
surrounding region with lower concentration are the basis of agar diffusion assay. 
Following an overnight incubation, the inhibition of bacteria is evident as a clear region, 
called “zone of inhibition” formed around the larval extract-containing well. This 
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antibacterial assay is an economical and easy way for the detection of bacterial 
susceptibility or resistance. 
 
 Results from the agar well diffusion assay (Figure4.2.3a) revealed the apparent 
potency of L. cuprina larval extract on P. aeruginosa. However, this assay failed to 
demonstrate the antibacterial activity of larval extract against the other six selected 
bacteria as no zones of bacterial growth inhibition was developed around wells 
containing L. cuprina larval extract (Figure 4.2.3b, Figure 4.2.3c, Figure 4.2.3d, Figure 
4.2.3e, Figure 4.2.3f, Figure 4.2.3g). Nonetheless, zones of bacterial growth inhibition 
were recorded for the formaldehyde positive controls for all bacteria tested (Table 
4.2.3).  
 
 Figure 4.2.3h illustrated the resulted diameter of inhibition zones surrounded the 
well containing larval extract in the P. aeruginosa agar plates was 19.60 ± 1.06 mm 
(n=10). Beyond these zones, the larval extract was apparently too diluted for 
bactericidal action. This result once again concurred with the findings reported by 
Huberman et al. (2007) whereby the three antibacterial molecules (p-hydroxybenzoic 
acid, p-hydroxyphenylacetic acid and proline diketopiperazine) isolated from the 
haemolymph extracts of L. sericata larvae demonstrated active antibacterial activity 
against P. aeruginosa in the zone inhibition assay and, furthermore, a combination of 
these molecules had even enhanced the inhibitory effect. The consistency of the present 
results with Huberman et al. (2007) proposes that larval extract (L. cuprina and L. 
sericata) is selectively inhibitory to the Gram-negative P. aeruginosa.  
 
 Besides, the inactivity of L. cuprina larval extract towards S. aureus and E. coli 
in the present study was in agreement with Bexfield et al. (2004) and van der Plas et al.  
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Figure 4.2.3a: Antibacterial activity of L. cuprina larval extract against bacteria using 
agar well diffusion assay 
 
 
 
 
 
 
  
  
Positive Control 
Positive Control 
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Figure 4.2.3b: Inactivity of L. cuprina larval extract against S. aureus in agar well 
diffusion assay 
 
 
 
 
 
 
Figure 4.2.3c: Inactivity of L. cuprina larval extract against MRSA in agar well 
diffusion assay 
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Figure 4.2.3d: Inactivity of L. cuprina larval extract against S. epidermidis in agar well 
diffusion assay 
 
 
 
 
 
 
Figure 4.2.3e:  Inactivity of L. cuprina larval extract against S. pyogenes in agar well 
diffusion assay 
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Figure 4.2.3f: Inactivity of L. cuprina larval extract against K. pneumoniae in agar well 
diffusion assay 
 
 
 
  
Figure 4.2.3g: Inactivity of L. cuprina larval extract against E. coli in agar well 
diffusion assay 
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Table 4.2.3: Diameter of inhibition zones produced in BHIA plates after overnight 
incubation  
 
Bacterial 
Species 
Diameter (mm) 
(Mean ± SD) 
Test Sample Well 
(with 100 mg/ml 
larval extract) 
Positive Control Well 
(with 5% 
formaldehyde) 
 
Negative Control Well 
(with sterile distilled 
water) 
 
S. aureus 
 
0 
 
40.6 ± 1.34 
 
0 
    
MRSA 0 45.8 ± 1.92 0 
    
S. epidermidis 0 42.6 ± 1.95 0 
    
S. pyogenes 0 50.8 ± 1.30 0 
    
K. pneumoniae 0 37.0 ± 1.22  0 
    
P. aeruginosa 19.60 ± 1.06 25.8 ± 0.84 0 
    
E. coli 0 31.4 ± 1.52 0 
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Figure 4.2.3h: Inhibition zones of P. aeruginosa (white-cycle) against L. cuprina larval 
extract in agar well diffusion assay 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
Positive Control  
Larval Extract 
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Positive Control  
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(2007) whereby they reported that the zone inhibition assay was ineffectual in 
determining the inhibition activity of L. sericata larval ES against S. aureus and E. coli. 
 
 On the other hand, in contrast with the results obtained by Huberman et al. 
(2007), Bexfield et al. (2004) and van der Plas et al. (2007), Kerridge et al. (2005) 
observed complete inhibitory effect of L. sericata larval ES against the Gram-positive 
bacteria S. aureus, MRSA and S. pyogenes but partial inhibitory effect against the 
Gram-negative bacteria P. aeruginosa and no inhibitory activity against E. coli as 
evidenced by partial halos zone of inhibition against P. aeruginosa and no zones of 
inhibition against E. coli. These opposing observations could be attributable to the 
different methods of larval ES processing.  Kerridge et al. (2005) used re-suspended 
freeze-dried L. sericata larval ES which was more concentrated and purified as 
compared to the centrifuged supernatant of ES [Bexfield et al. (2004), van der Plas et 
al. (2007)] for the examination of antibacterial activity. 
 
 
 As a whole, amongst the three antibacterial assays (TB, CFU and agar well 
diffusion assay) adopted in this study,  the TB assay was the most sensitive assay in 
detecting the antibacterial activity of L. cuprina larval extract as substantiated by the 
significant growth inhibition of the seven selected bacteria (Figure 4.2.1 a). This was 
due to the known variation in sensitivity of different types of bioassays that had been 
reported previously by Millar and Ratcliffe (1987), Kerridge et al. (2005) and Patton et 
al. (2006). Kerridge et al. (2005) found that TB assay was able to detect the 
antibacterial activity against some bacteria, particularly the vancomycin-resistant 
Enterococcus (VRE) which was previously undetected by the standard agar disc or well 
diffusion assay. The variation in the contact times of larval extract with the test bacteria, 
dilutions and method of collection of ES (Millar and Ratcliffe, 1987) as well as the 
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diffusion of larval extract through the agar matrix in the agar well diffusion assay are 
the contributing factors in influencing the efficacy of the corresponding bioassays. 
 
 Owing to the sensitivity of the turbidometric assay, it was used in the 
determination of minimum inhibitory concentration (MIC) and the physicochemical 
properties of larval extract against each selected bacterial species.  
 
4.2.4 Minimum Inhibitory Concentrations Assay 
Minimum inhibitory concentration (MIC) is defined as the lowest concentration of an 
antimicrobial agent at which no bacterial growth is detected after overnight incubation 
in growth medium. Besides the utilization by diagnostic laboratories principally to 
confirm resistance, MIC has also most often undertaken as a research tool to determine 
the in vitro activity of new antibacterial agents (Jennifer, 2001). MIC assay can be 
determined by agar dilution, broth macrodilution or broth microdilution method.  
 
 To the best of the author’s knowledge, the MICs of L. cuprina larval extract and 
even the extensively studied L. sericata larval ES for pathogenic bacteria have yet to be 
determined. Therefore, the present study adopted the broth microdilution antibacterial 
assay with some modifications to determine the MICs of L. cuprina larval extract for 
the seven selected bacteria spectrophotometrically as it is convenient and widely used 
for susceptibility testing of bacteria (Otvos and Cudic, 2007). For this study, the MIC 
endpoints of larval extract for each selected bacterial species are defined as the lowest 
concentration of larval extract (mg/ml) resulting in at least 50% bacterial growth 
inhibition relative to that of the corresponding controls. 
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 Table 4.2.4 summarizes the MICs of L. cuprina larval extract against the seven 
selected bacteria after overnight incubation in BHI media. In this study, twofold serial 
microdilutions of 100 mg/ml of larval extract were performed, ensued a final dilution 
range of 50, 25, 12.5, 6.25, 3.13, 1.56, 0.78 and 0.39 mg/ml. Again, the results obtained 
confirmed the apparent potency of L. cuprina larval extract against the Gram-negative 
bacteria, P. aeruginosa and E. coli. As little as 0.78 and 1.56 mg/ml larval extract were 
able to inhibit   59.17 ± 2.95% of P. aeruginosa and 56.71 ± 3.38%  (n = 5) of E. coli 
comparative to the respective growth controls. Conversely, the MICs of larval extract to 
inhibit at least 50% of bacterial growth for all selected Gram-positive bacteria and K. 
pneumoniae are 3.13 mg/ml.  
 
 However, the manifested antibacterial activity of L. cuprina larval extract 
against P. aeruginosa  was  not  supported  by  the  findings  reported  by  some  other  
researchers  who are working on L. sericata larvae. In the study undertaken by van der 
Plas et al. (2007), they reported that L. sericata larval ES at a concentration of 4.0 
mg/ml did not affect the viability of P. aeruginosa in the in vitro killing assay (CFU 
assay). Furthermore, Kerridge et al. (2005) have demonstrated that as concentrated as 
40 mg/ml of L. sericata larval ES was apparently inactive towards P. aeruginosa in the 
well diffusion assay. In addition, Barnes et al. (2010) employing the CFU assay had 
also revealed that as much as 1000 mg/ml L. sericata larval ES was needed to inhibit P. 
aeruginosa growth.  
 
 On the other hand, in contrary to the MIC of larval extract on S. aureus (3.13 
mg/ml) and E. coli (1.56 mg/ml) as determined by the present study, van der Plas et al. 
(2007) reported that 2.0 mg/ml L. sericata larval ES was able to exhibit antibacterial 
activity against S. aureus by reducing the number of viable S. aureus by 73 ± 10% (n =  
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Table 4.2.4: Broth microdilution MICs of L. cuprina larval extract against bacteria 
 
Bacteria MICs (mg/ ml) Bacterial Growth Inhibition (%) 
(as compared to growth controls, n= 5) 
S. aureus 3.13 60.90 ± 1.23 
 
MRSA 3.13 59.66 ± 3.53 
 
S. epidermidis 3.13 62.14 ± 3.12 
 
S. pyogenes 3.13 60.96 ± 5.78 
 
K. pneumoniae 3.13 62.30 ± 3.35 
 
P. aeruginosa 0.78 59.17 ± 2.95 
 
E. coli 1.56 56.71 ± 3.38 
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7) as compared with the controls. Nevertheless, in 2005, Kerridge et al. failed to detect 
the antibacterial activity of 40 mg/ml L. sericata larval ES against E. coli. However, 
recently, Barnes et al. (2010) found that 1000 mg/ml L. sericata larval ES was inactive 
towards S. aureus but yet was able to inhibit E. coli.  
 
 A review of the above findings has again demonstrated the generation of 
contradictory results on the potency of larval antibacterial activity against bacteria due 
to the variations in the sensitivity of different bioassays as discussed earlier and 
consequently, revealed the importance of selecting the most sensitive and appropriate 
bioassay to detect antibacterial activity. 
 
 Besides, it is also crucial to use growth media with a sufficiently high nutrient 
content for normal bacterial growth in the controls (Barnes et al. 2010) as this would 
have influenced the assessment of larval antibacterial activity as evidenced by the 
inconsistent results on P. aeruginosa and S. aureus obtained from the present study and 
the study conducted by van der Plas et al. (2007) who used growth medium consisted of 
10 mM sodium phosphate buffer and supplemented with only 1% TSB. This medium 
would not be adequate for normal bacterial growth in both the test samples and controls, 
hence they may possibly have underestimated the antibacterial activity of larval ES 
since the bacterial growth inhibition capacity of ES in the test samples was determined 
in comparison to the growth achieved in the controls in which optimum bacterial 
growth was impeded.  
  
 In addition, another factor that would have compounded the inconsistency of the 
antibacterial activity of larval products (crude extract or ES) is the type of diluents used 
to collect or reconstitute the larval products. In 1935, Simmons found that maggot 
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excretions diluted with normal saline (0.85% sodium chloride) was much more potent 
against bacteria than those diluted with sterile distilled water and he explained that this 
might be due to the effect of some physical change. Then, Bexfield et al. (2004) who 
collected larval native ES (nES) in sterile PBS reported that PBS might exert adverse 
effect on bacterial growth. Moreover, van der Plas et al. (2007) reported that the well 
diffusion assay was very sensitive in detecting the antibacterial activity of freeze-dried 
larval ES solubilized in 0.01% acetic acid. However, they might have overlooked the 
possibility that the use of acetic acid (a weak acid) had enhanced the sensitivity of well 
diffusion assay and the antibacterial activity of the ES against the tested bacteria. 
 
 Hence, it is imperative to standardize the preparation and quantification of larval 
products, type of bioassay employed, growth medium, method and diluents used during 
the collection and dilution of larval products in order to obtain consistent and 
comparable results of the potency of larval products. Barnes et al. (2010) had 
demonstrated that the number of larvae, bacterial species and nutritional values of 
growth medium did influence the antibacterial potency of larval ES.  
 
4.3 PHYSICOCHEMICAL PROPERTIES OF LARVAL EXTRACT 
 
The physicochemical properties of larval extract are very important in terms of 
development of a disinfectant product for medical purposes. However, it should be 
realized that this product is not recommended to replace the use of the live larvae but 
rather could be utilized in infection sites where the medicinal larvae cannot be 
employed. 
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4.3.1 Robustness 
As evidenced by the results shown in Figure 4.3.1a, L. cuprina larval extract which had 
been stored at -70°C for 13 months (red bars) exhibited broad spectrum antibacterial 
activity against all bacteria tested, while retaining a high degree of robustness as 
compared to the freshly prepared larval extract (blue bars). These results were affirmed 
by independent Student’s t-test that there was no significant loss of potency (p>0.05, 
n=5) in the 13-month-old L. cuprina larval extract against all bacteria tested as 
compared to the freshly prepared larval extract (Table 4.3.1a). In other words, the 13-
month-old larval extract was as potent as the freshly prepared ones. The average 
potency of the 13-month-old larval extract was 92.76 + 2.35% (Table 4.3.1b). 
 
 The results obtained were also supported by Duncan (1926) who investigated 
the bactericidal activity within the gut-content of several insects and arachnids. He 
observed that the dried materials collected from the gut-contents of certain insects 
retained the bactericidal activity after storing for at least six months. Additionally, 
Kerridge et al. (2005) had also reported that the lyophilized ES of L. sericata was able 
to withstand a long-term storage. 
 
 Nonetheless, there was a noticeable change in the colour of the 13-month-old 
larval extract. The colour of the long-term stored larval extract diluted in sterile distilled 
water was darker as compared to the control (Figure 4.3.1b). Nevertheless, these results 
had verified that vacuum-concentration of larval extract at 30˚C (to remove methanol by 
enhanced vacuum-evaporation) for seven hours did not result in detectable lost of 
antibacterial activity of L. cuprina larval extract against all bacteria tested. 
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Figure 4.3.1a: Potency of 13-month-old L. cuprina larval extract against bacteria in 
comparision to the controls (freshly prepared larval extract) 
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Table 4.3.1a: Comparison of mean potency of freshly prepared L. cuprina larval 
extract and 13-month-old L. cuprina larval extract against bacteria  
 
Bacterial Species TB Assay Mean ± SD 
 
t-statistics 
a 
(df) p value 
S. aureus Freshly Prepared 89.50 ± 1.97 0.84 (8) 0.427 
 13-month-old 90.41 ± 1.41   
MRSA Freshly Prepared 92.10 ± 3.26 -0.12 (8) 0.909 
 13-month-old 91.91 ± 1.34   
S. epidermidis Freshly Prepared 92.40 ± 1.27 -1.08 (8) 0.310 
 13-month-old 91.48 ± 1.41   
S. pyogenes Freshly Prepared 89.48 ± 3.93 0.58 (8) 0.581 
 13-month-old 90.50 ± 0.73   
K. pneumoniae Freshly Prepared 94.51 ± 0.95 -1.43 (8) 0.192 
 13-month-old 93.56 ± 1.15   
P. aeruginosa Freshly Prepared 95.71 ± 1.13 0.44 (8) 0.669 
 13-month-old 95.95 ± 0.42   
E. coli Freshly Prepared 96.10 ± 0.32 -2.26 (8) 0.054 
 13-month-old 95.49± 0.51   
 
a
 Two-tailed unpaired Student’s t-test 
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Table 4.3.1b: Mean potency of 13-month-old L. cuprina larval extract against bacteria  
 
Bacterial Species N Potency of Larval Extract (%) 
(Mean ± SD) 
S. aureus 5 90.41 ± 1.39 
   
MRSA 5 91.91 ± 1.34 
   
S. epidermidis 5 91.48 ± 1.41 
   
S. pyogenes 5 90.50 ± 0.73 
   
K. pneumoniae 5 93.56 ± 1.15 
   
P. aeruginosa 5 95.95 ± 0.42 
   
E. coli 5 95.49 ± 0.51 
   
 
Average Potency 
 
35 
 
92.76 + 2.35 
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Figure 4.3.1b: Change of colour in the 13-month-old L. cuprina larval extract (right) as 
compared to the freshly prepared larval extract (left) 
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4.3.2 Heat Stability 
On the other hand, to investigate the stability of the antibacterial activity of L. cuprina 
larval extract to heat, larval extract was boiled at 100°C for 5 minutes or autoclaved at 
121°C for 20 minutes. 
 
 Results from Figure 4.3.2 demonstrated the heat-resistant antibacterial activity 
of L. cuprina larval extract against all bacteria tested. Both boiled (green bars) and 
autoclaved (pink bars) larval extracts retained the bacterial growth inhibitory effect as 
no significant loss of potency was observed (p> 0.05, n=5) when compared with the 
corresponding controls (freshly prepared larval extract) (Table 4.3.2a, Table 4.3.2b). 
Additionally, the average potency of the boiled and autoclaved larval extracts were 
94.18 ± 1.65% and 93.36 ± 1.53% respectively (Table 4.3.2c). 
 
 The same observations had been reported by Simmons (1935) and Bexfield et 
al. (2004) who worked on L. sericata larval ES. As early as in 1935, Simmons proved 
that L. sericata larval ES autoclaved at 110˚C for 20 minutes was of heat-resistant 
properties and did not loss its antibacterial activity. He then concluded that the active 
principle(s) within the larval ES is of a non-viable nature. Furthermore, Bexfield et al. 
(2004) have also found that the heat-treated native ES (boiled at 100˚C for 8 minutes) 
from the larvae of L. sericata significantly reduced the CFUs  to  23%  of  the  control  
of  S. aureus,  whilst  the native ES enhanced bacterial growth to 123% of the control. 
They elucidated that these observations may be somewhat due to the deactivation of 
specific inhibitor(s) or activation of the antibacterial factor(s).  
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Figure 4.3.2: Potency of heat-treated L. cuprina larval extract against bacteria 
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Table 4.3.2a: Comparison of mean potency of freshly prepared L. cuprina larval 
extract and boiled L. cuprina larval extract against bacteria  
 
Bacterial Species TB Assay Mean ± SD 
 
t-statistics 
a 
(df) p value 
S. aureus Freshly Prepared 93.20 ± 1.56 1.025 (8) 0.335 
 Boiled 94.07 ± 1.07   
MRSA Freshly Prepared 92.18 ± 2.48 0.784 (8) 0.456 
 Boiled 93.22 ± 1.60   
S. epidermidis Freshly Prepared 92.19 ± 2.64 0.648 (8) 0.535 
 Boiled 93.14 ± 1.96   
S. pyogenes Freshly Prepared 91.96 ± 2.13 0.489 (8) 0.638 
 Boiled 92.48 ± 0.97   
K. pneumoniae Freshly Prepared 94.44 ± 0.78 1.327 (8) 0.221 
 Boiled 95.22 ± 1.04   
P. aeruginosa Freshly Prepared 96.56 ± 0.73 -1.558 (8) 0.158 
 Boiled 95.87 ± 0.67   
E. coli Freshly Prepared 95.62 ± 1.23 -0.569 (8) 0.585 
 Boiled 95.27 ± 0.66   
 
a
 Two-tailed unpaired Student’s t-test 
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Table 4.3.2b: Comparison of mean potency of freshly prepared L. cuprina larval 
extract and autoclaved L. cuprina larval extract against bacteria 
 
Bacterial Species TB Assay Mean ± SD 
 
t-statistics 
a 
(df) p value 
S. aureus Freshly Prepared 93.20 ± 1.56 -0.491 (8) 0.636 
 Autoclaved 92.81 ± 0.81   
MRSA Freshly Prepared 92.18 ± 2.48 0.745 (8) 0.478 
 Autoclaved 93.03 ± 0.51   
S. epidermidis Freshly Prepared 92.19 ± 2.64 0.150 (8) 0.884 
 Autoclaved 92.37 ± 0.72   
S. pyogenes Freshly Prepared 91.96 ± 2.13 -0.898 (8) 0.395 
 Autoclaved 91.08 ± 0.59   
K. pneumoniae Freshly Prepared 94.44 ± 0.78 0.065 (8) 0.950 
 Autoclaved 94.47 ± 0.68   
P. aeruginosa Freshly Prepared 96.56 ± 0.73 -2.122 (8) 0.067 
 Autoclaved 95.37 ± 1.03   
E. coli Freshly Prepared 95.62 ± 1.23 -2.007 (8) 0.080 
 Autoclaved 94.40± 0.59   
 
a
 Two-tailed unpaired Student’s t-test 
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Table 4.3.2c: Mean potency of boiled and autoclaved L. cuprina larval extract against 
bacteria  
 
Bacterial Species N Potency of Boiled                 
Larval Extract (%) 
(Mean ± SD) 
Potency of Autoclaved 
Larval Extract (%) 
(Mean ± SD) 
S. aureus 5 94.07 ± 1.07 92.81 ± 0.81 
    
MRSA 5 93.22 ± 1.60 93.03 ± 0.51 
    
S. epidermidis 5 93.14 ± 1.96 92.37 ± 0.72 
    
S. pyogenes 5 92.48 ± 0.97 91.08 ± 0.59 
    
K. pneumoniae 5 95.22 ± 1.04 94.47 ± 0.68 
    
P. aeruginosa 5 95.87 ± 0.67 95.37 ± 1.03 
    
E. coli 5 95.27 ± 0.66 94.40± 0.59 
    
 
Average Potency 
 
35 
 
94.18 + 1.65 
 
93.36 + 1.53 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
85 
 
 Nevertheless, Kerridge et al. (2005) who also investigated the heat stability of L. 
sericata larval ES have reported that boiling of larval ES resulted in a complete loss in 
antibacterial activity  against  MRSA  and  they  stated  the  possible  explanation  for  
the  failure to detect the activity of the boiled ES was the lower sensitivity of the agar 
well diffusion assay as compared to liquid culture assay. 
 
4.3.3 Freeze-Thaw Stability 
Besides robustness and thermal stability, the freeze-thaw stability of larval extract is 
one of the important physicochemical properties to be considered in developing a novel 
disinfectant as well. Results from Figure 4.3.3 demonstrated that the larval extract 
which had been freeze-thawed for ten cycles was as potent as the control against all 
bacteria in the TB assay and this result was affirmed by independent Student’s t-test as 
there was no significant loss of potency (p>0.05, n=5) (Table 4.3.3a) in the repeatedly 
freeze-thawed larval extract as compared to the freshly prepared ones and yet had an 
average potency of 92.24 ± 3.27% (Table 4.3.3b). 
 
 These results were again agreed with the findings reported by Bexfield et al. 
(2004) and Kerridge et al. (2005) whereby they affirmed that the antibacterial activity 
of L. sericata larval ES which has undergone several freeze-thaw cycles remained 
unaffected. 
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Figure 4.3.3: Potency of freeze-thawed L. cuprina larval extract against bacteria 
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Table 4.3.3a: Comparison of mean potency of freshly prepared L. cuprina larval 
extract and freeze-thawed L. cuprina larval extract against bacteria  
 
Bacterial Species TB Assay Mean ± SD 
 
t-statistics 
a 
(df) p value 
S. aureus Freshly Prepared 89.08 ± 2.47 -0.517 (8) 0.619 
 Freeze-thawed 89.92 ± 2.70   
MRSA Freshly Prepared 91.05 ± 2.70 -0.049 (8) 0.962 
 Freeze-thawed 91.13 ± 2.43   
S. epidermidis Freshly Prepared 91.85 ± 2.66 -0.202 (8) 0.845 
 Freeze-thawed 92.19 ± 2.64   
S. pyogenes Freshly Prepared 88.69 ± 2.65 0.340 (8) 0.742 
 Freeze-thawed 88.03 ± 3.40   
K. pneumoniae Freshly Prepared 94.05 ± 0.70 -0.668 (8) 0.523 
 Freeze-thawed 94.39 ± 0.90   
P. aeruginosa Freshly Prepared 95.43 ± 0.85 -1.045 (8) 0.327 
 Freeze-thawed 96.05 ± 1.01   
E. coli Freshly Prepared 95.57 ± 1.25 -0.072 (8) 0.945 
 Freeze-thawed 95.62 ± 1.22   
 
a
 Two-tailed unpaired Student’s t-test 
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Table 4.3.3b: Mean potency freeze-thawed L. cuprina larval extract against bacteria  
 
Bacterial Species N Potency of Larval Extract (%) 
(Mean ± SD) 
S. aureus 5 89.92 ± 2.70 
   
MRSA 5 91.13 ± 2.43 
   
S. epidermidis 5 92.19 ± 2.64 
   
S. pyogenes 5 88.03 ± 3.40 
   
K. pneumoniae 5 94.39 ± 0.90 
   
P. aeruginosa 5 96.05 ± 1.01 
   
E. coli 5 95.62 ± 1.22 
   
 
Average Potency 
 
35 
 
92.24 + 3.27 
 
 
 
 
 
 
